Allergan Plc (NYSE:AGN)

CAPS Rating: 4 out of 5

The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products.

Caps

How do you think AGN will perform against the market?

Add Stock to CAPS Watchlist

All Players

413 Outperform
30 Underperform
 

All-Star Players

100 Outperform
7 Underperform
 

Wall Street

17 Outperform
0 Underperform
 

Top AGN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

bradford86 (99.77)
Submitted January 14, 2012

276. Watson Pharmaceuticals (NYSE: WPI) is down from $70 where it topped in 2011. At the present price of around $62, I think that there is a little upside here. Target: $63-$68. My 2012 EPS estimate is $5.60 which puts this at a P/E of 11.1 for a… More

naughtyguy (34.47)
Submitted March 13, 2014

34 billion market cap! You have got to be kidding!

AGN VS S&P 500 (SPY)

Fools bullish on AGN are also bullish on:

Fools bearish on AGN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about AGN.

Recs

0
Member Avatar LLCoolJosh (80.14) Submitted: 5/11/2017 1:11:10 PM : Outperform Start Price: $230.76 AGN Score: -4.96

Beneficiary of the "selfie-generation".

Recs

0
Member Avatar Ajormond (63.46) Submitted: 5/10/2017 12:20:19 PM : Underperform Start Price: $228.69 AGN Score: +3.86

the market has taken a harsh stance on the company after the most recent quarter results for various reasons. I agree that those are all valid for the short term decline. The bigger issue that I see that has yet to be reported is the significant concern there should be with the eye care segment of the business. There was a decline in YOY glaucoma medications due to generic pressures as identified by the company. The bigger concern that was not discussed was the pitiful YOY growth of Restasis. 3% YOY growth, despite a 9-9.9% price increase (depending on the report you read) No matter how you slice it, that is YOY sales decline on their billion dollar eye drop. This is a very bearish statistic when put in the light of the Shire report of 22% market share for Xiidra during their Q! report. That means that the prescribers are writing and having success with the competitor drug. Add to that the recent agreement to allow exclusivity of a generic version of the drug to be produced, and this may be the start of the race to the bottom in margins for that entire segment of eye care. I don't see anything in the pipeline that will help in that regard.

Recs

0
Member Avatar sojournerks (98.17) Submitted: 3/7/2017 9:03:39 AM : Outperform Start Price: $238.54 AGN Score: -8.86

Stock that begins paying dividends should be considered

Leaderboard

Find the members with the highest scoring picks in AGN.

Score Leader

darkstrike2

darkstrike2 (< 20) Score: +893.25

The Score Leader is the player with the highest score across all their picks in AGN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
caahfer 89.86 10/10/2008 Outperform 3Y $22.06 +910.62% +187.24% +723.38 0 Comment
rustat82 90.95 11/22/2006 Outperform 1Y $24.64 +804.93% +83.04% +721.89 0 Comment
stockssmocks 93.91 10/15/2008 Outperform NS $22.98 +870.09% +155.63% +714.46 0 Comment
Sempre57 26.69 11/22/2006 Outperform 3W $24.88 +796.05% +82.98% +713.06 0 Comment
blazin1 < 20 11/21/2006 Outperform 3M $24.92 +794.85% +83.38% +711.48 0 Comment
snoopaloop 25.60 11/20/2006 Outperform 5Y $24.95 +793.78% +83.83% +709.95 0 Comment
ocdan 83.43 10/22/2008 11/10/2009 Outperform 3Y $22.77 +879.39% +169.46% +709.93 0 Comment
trustee74 84.82 12/8/2006 Outperform 3Y $25.22 +783.95% +83.02% +700.93 0 Comment
juliehowe 62.43 10/28/2008 Outperform 3Y $22.74 +880.67% +183.79% +696.88 0 Comment
NetscribePhrmtcl 91.98 1/17/2007 Outperform 1Y $25.57 +771.96% +80.47% +691.48 2 Comments

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
trackmizuho < 20 8/19/2016 Outperform NS $250.97 -11.16% +11.26% -22.42 0 Comment
TrackDeutscheSec 88.11 7/23/2014 Outperform NS $215.91 +3.27% +22.37% -19.10 0 Comment
TrackCanaccord 58.44 6/27/2014 Outperform NS $222.54 +0.19% +24.58% -24.38 0 Comment
TrackJimCramer 84.78 6/17/2013 Outperform 3W $123.83 +80.06% +47.71% +32.35 0 Comment
TrackCRTCapital 58.04 5/13/2013 Outperform NS $117.82 +89.25% +48.84% +40.42 0 Comment
TrackPiperJaff 86.86 11/2/2012 Outperform NS $87.61 +154.51% +69.06% +85.46 0 Comment
TrackCreditSuiss 90.29 11/1/2012 Outperform NS $89.20 +149.96% +71.48% +78.48 0 Comment
TrackZacks < 20 10/19/2012 Outperform 3M $86.91 -1.70% -3.41% +1.70 11/12/2012 @ $85.43 1 Comment
TrackZacks < 20 8/27/2012 Outperform 3M $82.65 +5.48% +1.88% +3.60 10/9/2012 @ $87.18 1 Comment
TrackBernstein 93.07 6/22/2012 Outperform NS $70.18 +217.70% +82.45% +135.25 0 Comment
TrackZacks < 20 5/17/2012 Outperform 3M $70.87 +10.64% +8.33% +2.31 8/21/2012 @ $78.41 1 Comment
TrackCitigroup 93.24 4/26/2012 Outperform NS $75.08 +196.98% +74.89% +122.10 0 Comment
TrackJPMorgan 88.99 4/26/2012 Outperform NS $75.08 +196.98% +74.89% +122.10 0 Comment
TrackZacks < 20 4/5/2012 Outperform 3M $67.56 +10.14% +0.26% +9.87 4/26/2012 @ $74.41 1 Comment
TrackBarclaysCap 91.67 12/9/2011 Outperform NS $61.94 +274.36% +57.80% +216.56 9/23/2014 @ $231.88 0 Comment
TrackGoldmanSach 71.31 10/20/2011 Outperform 5Y $66.63 +234.44% +68.64% +165.80 5/13/2016 @ $222.84 1 Comment
TrackCollinsStew 77.53 7/26/2011 Outperform NS $67.96 +228.08% +81.88% +146.20 0 Comment
TrackZacks < 20 7/25/2011 Outperform 3M $69.36 -13.25% +4.66% -17.91 3/13/2012 @ $60.17 1 Comment
TrackZacks < 20 6/21/2011 Outperform 3M $65.70 -0.38% -1.17% +0.79 6/27/2011 @ $65.45 1 Comment
TrackZacks < 20 5/27/2011 Outperform 3M $63.99 +0.75% -3.81% +4.56 6/8/2011 @ $64.47 1 Comment
TrackArgus 91.32 10/4/2010 Outperform NS $43.35 +414.32% +112.38% +301.94 0 Comment
TrackNeedham 91.38 3/4/2010 Underperform NS $39.94 +7.01% +7.19% +0.18 4/16/2010 @ $42.74 0 Comment
TrackPiperJaff 86.86 3/4/2010 Underperform NS $39.94 +121.31% +27.50% -93.81 11/2/2012 @ $88.39 0 Comment
TrackSunTrustRH 84.34 12/10/2009 Outperform NS $37.99 +106.98% +25.00% +81.97 7/30/2012 @ $78.63 0 Comment
TrackRBCCapMkts 88.16 4/23/2009 Outperform NS $29.03 +668.06% +189.73% +478.33 0 Comment
TrackStanfordRes < 20 1/22/2009 Outperform NS $24.33 +174.97% +67.35% +107.62 4/17/2012 @ $66.90 0 Comment
TrackCreditSuiss 90.29 11/6/2008 Underperform NS $24.40 +250.33% +49.78% -200.54 10/31/2012 @ $85.48 0 Comment
TrackWellsFargo 91.53 9/22/2008 Outperform NS $28.72 +676.28% +100.02% +576.26 0 Comment
TrackJimCramer 84.78 9/4/2008 Underperform 3W $30.26 +312.89% +32.58% -280.31 6/17/2013 @ $124.94 0 Comment
TrackJimCramer 84.78 7/21/2008 Outperform 3W $29.30 +3.28% -1.60% +4.88 9/4/2008 @ $30.26 0 Comment
TrackSoros 86.82 3/31/2008 Outperform NS $29.06 +667.27% +90.87% +576.41 1 Comment
TrackWRHambrecht < 20 2/19/2008 Outperform NS $28.52 +134.57% +0.91% +133.66 4/17/2012 @ $66.90 0 Comment
TrackEdwardOwens 99.76 9/30/2007 Outperform NS $32.11 +594.34% +66.79% +527.54 2 Comments
TrackRothCapital 67.54 9/28/2007 Outperform NS $33.00 +89.06% -11.42% +100.48 5/3/2011 @ $62.39 0 Comment
TrackUBS 93.55 5/2/2007 Outperform NS $29.74 +649.63% +72.46% +577.17 0 Comment
TrackRothCapital 67.54 11/8/2006 Outperform NS $25.45 +5.11% +2.14% +2.97 2/28/2007 @ $26.75 0 Comment
TrackJimCramer 84.78 10/27/2006 Underperform 3W $26.67 +9.86% -8.30% -18.16 7/22/2008 @ $29.30 0 Comment
TrackFTNEquityCa < 20 10/17/2006 Outperform NS $26.56 +151.88% +1.17% +150.71 4/17/2012 @ $66.90 0 Comment

Featured Broker Partners